AACR 2024: PDC*line Pharma presents interim clinical results from last cohort of patients in phase I
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...